The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years.
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain, while reducing the effects ...
Stocks traded mostly lower on Friday after President Donald Trump followed through on his pledge to enact tariffs on Mexico ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...